Business
GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that Bob Ragusa will retire as Chief Executive Officer, effective June 1, 2026. GRAIL's Board of Directors has appointed the Company's President, Josh Ofman, MD, MSHS, to serve as GRAIL's Chief Executive Officer upon Ragusa's retirement. In addition, Ofman has been appointed to GRAIL's Board of Directors, effective immediately. Ofman's appointment is the culmination of a
About this update from Illumina, Inc.
[{"type":"text","content":"MENLO PARK, Calif., March 12, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that Bob Ragusa will retire as Chief Executive Officer, effective June 1, 2026. GRAIL's Board of Directors has appointed the Company's President, Josh Ofman, MD, MSHS, to serve as GRAIL's Chief Executive Officer upon Ragusa's retirement. In addition, Ofman has been appointed to GRAIL's Board of Directors, effective immediately. Ofman's appointment is the culmination of a long-term comprehensive succession planning process to ensure leadership continuity and strategic execution. Ragusa will remain on GRAIL's Board until June 1, 2026, and plans to serve in a senior advisory role through March of 2027.","length":812,"tagName":"p"},{"type":"image","alt":"GRAIL, Inc. is a healthcare company whose mission is to detect cancer early when it can be cured. (PRNewsfoto/GRAIL, Inc.)","displaySize":"","headline":null,"caption":"GRAIL, Inc. is a healthcare company whose mission is to detect cancer early when it can be cured. (PRNewsfoto/GRAIL, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":76,"url":"https://media.zenfs.com/en/prnewswire.com/df6f1c041e7249704f56bfd0aaad45cf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LnMp0pobetiqZw3skecvAA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEzNDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/df6f1c041e7249704f56bfd0aaad45cf","width":400,"height":76}},"href":"https://mma.prnewswire.com/media/2460831/Grail_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""Bob's leadership during a pivotal period — including the spinout from Illumina, commercial growth, and the scaling of our North Carolina laboratory operations — has been instrumental in strengthening GRAIL's foundation for long-term growth," said Greg Summe, Chairman of GRAIL's Board. "His operational expertise and commitment to excellence have positioned the company to advance multi-cancer early detection at scale. On behalf of the Board, we thank him for his significant contributions and dedicated service."","length":547,"tagName":"p"},{"type":"text","content":""Multi-cancer early detection has the potential to redefine cancer care and ...